Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.
about
New antibody approaches to lymphoma therapyChallenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological MalignancySuccessful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia.First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.Overview of alemtuzumab therapy for the treatment of T-cell lymphomas.Novel and emerging targeted-based cancer therapy agents and methods.Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia.Treatment options for high-risk chronic lymphocytic leukaemia.Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational usePractical approach to management of chronic lymphocytic leukemiaChronic lymphocytic leukemia: treatment of relapse.Chronic lymphocytic leukemia: putting new treatment options into perspective.Infections associated with monoclonal antibody and fusion protein therapy in humans.Front-line therapy for chronic lymphocytic leukemia.Treatment of relapsed or refractory chronic lymphocytic leukemia.Viral infections and their management in patients with chronic lymphocytic leukemia.Alemtuzumab and myelodysplasia: a story of love and hate (possible alemtuzumab-induced myelodysplastic changes).Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.Stability of alemtuzumab solutions at room temperature.Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients.Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.Correction to: Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.T cell depletion utilizing CD34+ stem cell selection and CD3+ addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients
P2860
Q27022373-34B7B20B-335D-4C9C-B1DF-AC1F9F6190C9Q28080304-75D25CF8-E761-44E8-AD47-FEAC8A380BE9Q33394308-9C4C6AE3-3B65-49B8-8FC4-16106D1C7468Q33407700-1C9E6586-CB88-499F-9FEF-140CC1C41AA8Q33956034-35D03E83-5BFC-4DA1-B842-BF4D56C7D21EQ34008593-6E8654A8-7903-455F-A66B-02C1231C8908Q34222228-04126278-56DA-42AC-9F46-49DE0087C15FQ35558057-58C95AF8-B1CA-40E6-B426-2A40E12510E3Q35664328-8CDE0D55-6E8D-4110-8537-3BFE7563F07DQ36612587-5DE473C9-E22F-4963-B334-F0616D7CC388Q36768605-EEAA9EC7-9794-4244-9ACE-5DD50EBA30ADQ36845277-E878A51F-B5CF-4022-91BF-5924665E6901Q36852238-C38FE014-28B3-4E1B-8439-F74E07E03645Q37734199-96BCB687-B56A-482C-B400-737C2CAB9C04Q37912944-80355B59-994A-489C-9FBA-D290D6119550Q37964914-46EB997A-C372-4EF0-88CC-FEB631E0BF9DQ37964916-9313993B-90FB-49E5-AC96-47DA6DB64EDBQ38064527-7F420530-8CF9-4A6E-BD61-AB11E54A60C1Q38069054-A5BB8BE3-B221-4D32-906E-24E3EEE0B018Q38397004-4A833B7A-A862-4DEC-8CA3-6E782F965791Q38579008-C50370F9-85A7-4259-8420-E3DB8B1138C3Q41095380-8095A321-D925-4031-B756-26C539EE73DEQ41137752-A84318C9-3A52-4E2C-B2AA-2F2DDCD35357Q41457221-10F334B5-B01E-497F-A045-AA3DF0C47FFEQ42217632-8413199A-A7AD-4667-90ED-60C84D4F427AQ43477578-083780D4-B2E9-4903-9E24-B7D1BBFF5446Q44100215-1F3FA05D-7FB0-455E-A7A2-F6367F843684Q45876740-2B9B9AB5-FD77-4083-AEEA-34CB79ED47C9Q55045610-B989D36C-B905-4A7D-9406-9DA357A39685Q58449860-639DB1AA-BD53-4A46-9749-19147FB0FC4A
P2860
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.
@en
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.
@nl
type
label
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.
@en
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.
@nl
prefLabel
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.
@en
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.
@nl
P2093
P2860
P356
P1433
P1476
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.
@en
P2093
A Osterborg
C-M Wendtner
M H J van Oers
M J S Dyer
M Montillo
R F Bezares
P2860
P2888
P304
P356
10.1038/LEU.2009.146
P577
2009-07-23T00:00:00Z